Evenity (Romosozumab) and Levothyroxine Interaction

Why This Combination Comes Up So Often

Hypothyroidism and osteoporosis frequently coexist, especially in postmenopausal women over 60. About 12.5 million Americans take levothyroxine daily, making it one of the most prescribed medications in the country [1]. Romosozumab (brand name Evenity), approved by the FDA in April 2019 for osteoporosis in postmenopausal women at high fracture risk, is increasingly prescribed after the landmark FRAME and ARCH trials demonstrated its ability to both build new bone and reduce fracture incidence [2].

A Common Clinical Scenario

Many patients starting romosozumab are already on stable levothyroxine therapy. Clinicians and patients alike want to know whether these drugs interfere with each other. The short answer: they do not interact through traditional pharmacokinetic pathways. But the longer, more useful answer requires understanding how thyroid hormone status itself affects bone metabolism.

Why Traditional Interaction Databases Show "No Known Interaction"

Standard drug interaction checkers (Lexicomp, Micromedex, Clinical Pharmacology) do not flag a romosozumab-levothyroxine pair. This is accurate from a metabolism standpoint. Romosozumab is a humanized IgG2 monoclonal antibody cleared through proteolytic degradation, not hepatic CYP450 enzymes or P-glycoprotein transporters [2]. Levothyroxine is absorbed in the jejunum and ileum and metabolized by deiodination, glucuronidation, and sulfation [3]. These pathways do not overlap.

Pharmacokinetic Profile: No Direct Conflict

Romosozumab and levothyroxine occupy entirely different pharmacokinetic compartments. Understanding why they do not compete for absorption, distribution, or metabolism requires a brief look at each drug's profile.

Romosozumab Bypasses the GI Tract

Romosozumab is administered as two 105 mg subcutaneous injections (210 mg total) once monthly. Peak serum concentration occurs approximately 5 days post-injection, and steady-state is reached by the third monthly dose [2]. Because the drug never enters the gastrointestinal lumen, it cannot interfere with the oral absorption of levothyroxine or any other orally administered medication.

Levothyroxine Absorption Is GI-Dependent

Levothyroxine requires an acidic gastric environment and an empty stomach for optimal absorption. Bioavailability ranges from 40% to 80% depending on the formulation and GI conditions [3]. Medications that alter gastric pH (proton pump inhibitors), bind levothyroxine in the gut (calcium carbonate, iron supplements, cholestyramine), or accelerate GI transit can reduce levothyroxine absorption significantly. Romosozumab does none of these things.

No CYP450 or Transporter Overlap

Monoclonal antibodies like romosozumab are too large (approximately 149 kDa) to serve as substrates, inhibitors, or inducers of CYP450 enzymes [4]. They are also not transported by P-glycoprotein or organic anion transporters. Levothyroxine, while it undergoes hepatic metabolism, is not a meaningful CYP450 substrate in the traditional sense. There is no mechanistic basis for a pharmacokinetic interaction.

The Real Concern: Pharmacodynamic Interference

The absence of a pharmacokinetic interaction does not mean thyroid status is irrelevant during romosozumab therapy. The pharmacodynamic relationship between thyroid hormones and bone remodeling is well established and clinically significant.

How Excess Thyroid Hormone Damages Bone

Triiodothyronine (T3), the active form of thyroid hormone, binds thyroid hormone receptor alpha (TRα) on osteoblasts and osteoclasts. Supraphysiologic T3 levels shift the remodeling balance toward net bone loss by shortening the bone formation phase and prolonging the resorption phase of each remodeling cycle [5]. A meta-analysis published in JAMA (Bauer et al., 2001; N=686 women) found that postmenopausal women with TSH <0.1 mIU/L had a 3.6-fold higher risk of hip fracture compared with euthyroid women (95% CI 1.0 to 12.9) [6].

Subclinical Hyperthyroidism and Bone Loss

Even mildly suppressed TSH (0.1 to 0.44 mIU/L) has been linked to increased bone turnover markers, including serum C-terminal telopeptide (CTX) and procollagen type 1 N-propeptide (P1NP) [7]. In patients receiving romosozumab specifically to increase P1NP and suppress CTX, an over-replaced thyroid state could blunt the expected biomarker response and reduce the drug's clinical benefit.

The Clinical Implication

If a patient's levothyroxine dose is too high, the resulting thyroid hormone excess may partially counteract romosozumab's dual mechanism of action (increased bone formation via sclerostin inhibition and decreased bone resorption). This does not mean the drugs "interact" in the pharmacokinetic sense. It means that optimizing thyroid replacement is a prerequisite for maximizing romosozumab efficacy.

Monitoring Protocol for Co-Administration

A structured monitoring approach ensures that both drugs perform optimally during the 12-month romosozumab treatment window.

Baseline Assessment Before Starting Romosozumab

Before the first romosozumab injection, clinicians should confirm that TSH is within the target range. For most hypothyroid patients on replacement therapy, the target TSH is 0.5 to 2.5 mIU/L [8]. Patients with a history of thyroid cancer on intentional TSH suppression require a separate risk-benefit discussion, because their TSH targets may be 0.1 to 0.5 mIU/L or lower depending on recurrence risk.

Baseline labs should include:

• TSH and free T4
• Serum calcium and 25-hydroxyvitamin D
• P1NP (bone formation marker)
• CTX (bone resorption marker)
• Comprehensive metabolic panel including creatinine

During the 12-Month Treatment Course

TSH should be rechecked at 6 to 8 weeks after any levothyroxine dose change and at least once during the romosozumab course if the dose has been stable [3]. Bone turnover markers (P1NP and CTX) can be measured at 1, 6, and 12 months to track romosozumab's pharmacodynamic effect. In the FRAME trial (N=7,180), romosozumab increased P1NP by 145% at month 1 and suppressed CTX by 35% at month 6 relative to placebo [9]. A failure to see expected marker changes should prompt re-evaluation of thyroid status, vitamin D levels, and medication adherence.

Post-Romosozumab Transition

After 12 months of romosozumab, guidelines recommend transitioning to an antiresorptive agent (typically denosumab or a bisphosphonate) to maintain the bone density gains [10]. This transition period is another point where thyroid optimization matters, since the antiresorptive agent must hold the gains that romosozumab produced.

Dose Timing and Practical Administration

One of the most common patient questions involves timing. Levothyroxine has strict administration requirements that do not apply to romosozumab, but patients on multiple medications need a clear schedule.

Levothyroxine Timing Rules

Levothyroxine should be taken on an empty stomach, 30 to 60 minutes before the first meal. It should be separated from calcium and iron supplements by at least 4 hours [3]. These rules exist because of GI absorption sensitivity. None of these timing constraints apply to romosozumab.

Romosozumab Administration

Romosozumab injections are given once monthly in a clinical setting (abdomen, thigh, or upper arm). The injection can be administered at any time of day regardless of meals. There is no requirement to separate the injection from oral medications by any time interval, because the subcutaneous and oral routes do not share an absorption pathway.

Same-Day Administration Is Fine

A patient can take levothyroxine in the morning per their usual routine and receive a romosozumab injection later that day without concern. No dose adjustment of either medication is needed based on co-administration timing.

Special Populations

Certain patient groups require additional attention when romosozumab and levothyroxine are used together.

Post-Thyroidectomy Patients

Patients who have undergone total thyroidectomy for thyroid cancer are entirely dependent on exogenous levothyroxine. Their TSH targets are often intentionally suppressed below the normal range to reduce cancer recurrence risk. The 2015 American Thyroid Association guidelines stratify TSH suppression by recurrence risk category [8]. For low-risk patients in remission, the target TSH is 0.5 to 2.0 mIU/L. For high-risk patients, the target may be <0.1 mIU/L.

In the high-risk category, the bone cost of TSH suppression must be weighed against the cancer benefit. Dr. Douglas Ross, writing in the 2016 Endocrine Society clinical practice guideline, noted: "Clinicians should aim for the minimum degree of TSH suppression necessary to achieve the oncologic goal, particularly in postmenopausal women at risk for osteoporosis" [8]. Romosozumab may provide a window of bone protection during a period of intentional TSH suppression, but this use has not been studied in a dedicated trial.

Elderly Patients (Over 75)

Both the ARCH trial (romosozumab vs. Alendronate, N=4,093) and the FRAME trial enrolled patients with a mean age of approximately 71 years [9][11]. Romosozumab carries a boxed warning about increased risk of myocardial infarction, stroke, and cardiovascular death. Elderly patients on levothyroxine should have their cardiovascular risk assessed independently. Excess thyroid hormone is itself a risk factor for atrial fibrillation and cardiac events, adding another reason to keep TSH within range [5].

Patients with Malabsorptive Conditions

Celiac disease, inflammatory bowel disease, and gastric bypass surgery can impair levothyroxine absorption, leading to fluctuating TSH levels. These patients may benefit from liquid levothyroxine formulations (Tirosint-SOL) or softgel capsules (Tirosint), which are less pH-dependent [3]. Stabilizing thyroid levels before and during romosozumab therapy improves the predictability of bone marker responses.

Cardiovascular Safety Considerations

The ARCH trial revealed a statistically significant increase in adjudicated serious cardiovascular events with romosozumab compared with alendronate during the first 12 months (2.5% vs. 1.9%) [11]. This led to the FDA boxed warning advising against romosozumab use in patients who have had a myocardial infarction or stroke within the preceding year.

Thyroid Excess Adds Cardiovascular Risk

Hyperthyroidism and subclinical hyperthyroidism independently raise the risk of atrial fibrillation, heart failure, and coronary events [5]. A Danish population-based cohort study (Collet et al., 2012; N=55,451) found that subclinical hyperthyroidism was associated with increased total mortality (HR 1.24, 95% CI 1.06 to 1.46) and coronary heart disease mortality (HR 1.29, 95% CI 1.02 to 1.62) [12].

The Compound Risk Argument

While no study has examined the combination of romosozumab with excess levothyroxine as a specific cardiovascular risk factor, the additive logic is straightforward. A patient with suppressed TSH and concurrent romosozumab use is exposed to two independent sources of cardiovascular risk. Keeping TSH within the euthyroid range eliminates one of those sources without requiring any change to the romosozumab prescription.

What the FDA Labels Say

The Evenity (romosozumab) prescribing information does not list levothyroxine as an interacting drug. It states: "No formal drug interaction studies have been conducted with EVENITY" [2]. The levothyroxine prescribing information lists numerous absorption interactions (calcium, iron, antacids, bile acid sequestrants) but does not mention monoclonal antibodies [3].

The absence of a listed interaction reflects the lack of a pharmacokinetic mechanism, not a lack of clinical relevance. The pharmacodynamic relationship between thyroid status and bone metabolism is covered in endocrinology guidelines rather than in individual drug labels.

Key Takeaways for Clinicians

The American Association of Clinical Endocrinology (AACE) 2020 postmenopausal osteoporosis guideline recommends identifying and correcting secondary causes of bone loss before initiating anabolic therapy [10]. Thyroid hormone excess is listed as a recognized secondary cause. Confirming euthyroid status before starting romosozumab is not optional. It is part of the standard workup.

For patients already on stable, well-dosed levothyroxine with TSH in range, romosozumab can be added without dose modification of either drug. For patients with unstable TSH or intentional TSH suppression, a collaborative discussion between the prescribing endocrinologist and the patient is warranted.

The 12-month treatment window for romosozumab is short. Maximizing bone formation during that window means eliminating modifiable factors that oppose it. Levothyroxine over-replacement is one such factor, and it is entirely correctable.